Select GI AEs Managed in Studies of Nivolumab, Ipilimumab in Melanoma in Pooled Post-Hoc Analysis
June 5th 2017Nivolumab (Opdivo) plus ipilimumab (Yervoy) or ipilimumab alone are associated with a high incidence of gastrointestinal (GI) toxicity, but most adverse events (AEs) are effectively managed using immunomodulators, which do not appear to inhibit tumor response. Additionally, nivolumab plus ipilimumab significantly improved overall survival (OS) and objective response rate (ORR) versus ipilimumab alone in patients with untreated advanced melanoma.
Read More
Immune Component May Affect Survival after Targeted Therapy for Melanoma
June 5th 2017Overall survival in advanced melanoma treated with targeted therapy had a strong association with high PD-L1 expression and high levels of tumor infiltrating lymphocytes, analysis of tissue specimens from a randomized trial showed.
Read More
An Overview of a Study Exploring Mirvetuximab Soravtansine in Ovarian Cancer
June 5th 2017Kathleen N. Moore, MD, assistant professor, The Stephenson Cancer Center, The University of Oklahoma, discusses results of an ongoing clinical trial exploring mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant epithelial ovarian cancer patients, during the 2017 ASCO Annual Meeting.
Watch
Results of the LATITUDE Trial in High-Risk Metastatic Hormone-Naive Prostate Cancer
June 5th 2017Kim Chi, MD, professor, University of British Columbia, discusses results of the phase III LATITUDE trial of androgen deprivation therapy with abiraterone acetate plus prednisone (Deltasone) or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer.
Watch
Niraparib Improves Responses in Recurrent Ovarian Cancer, Analysis Shows
June 5th 2017The PARP inhibitor niraparib (Zejula) provided significant benefits in patients with recurrent ovarian cancer who had a partial response, with similar treatment effects in patients with or without germline <em>BRCA</em> mutations, according to a post-hoc analysis of data from the ENGOT-OV16/NOVA trial presented at the 2017 ASCO Annual Meeting.
Read More
Reducing oxaliplatin-based chemotherapy by half could benefit patients with low-risk advanced colon cancer receiving chemotherapy after surgery. The 50% decrease would not notably increase their recurrence risk and would decrease the chances of developing neuropathy, according to findings presented at the 2017 ASCO Annual Meeting.
Read More
ORR Raised to 85% With Neoadjuvant, Adjuvant Dabrafenib/Trametinib Combo
June 4th 2017Neoadjuvant and adjuvant dabrafenib (Tafinlar) plus trametinib (Mekinist) increased the overall response rate (ORR) to 85% in patients with high-risk resectable <em>BRAF</em>-mutant metastatic melanoma. And interestingly, the pathologic complete response (pCR) rate with the combination was 58%, as demonstrated in findings presented during the 2017 ASCO Annual Meeting.
Read More
Five-Year OS Data for Dabrafenib/Trametinib Combo in Melanoma
June 4th 2017Georgina V. Long, BSc, PhD, MBBS, professor of medical melanoma oncology, Melanoma Institute Australia, discusses 5-year overall survival data from a phase II trial of dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with <em>BRAF V600</em>-mutant unresectable or metastatic melanoma during the 2017 ASCO Annual Meeting.
Watch
Olaparib/Cediranib Combination Leads to Continued PFS Improvement in Ovarian Cancer
June 4th 2017Progression-free survival (PFS) continues to be superior with the combination of cediranib maleate and olaparib (Lynparza) compared with olaparib alone in patients with recurrent platinum-sensitive ovarian cancer in a randomized open-label study with follow-up to December 2016.
Read More
No QoL Decrement With Olaparib for Recurrent Ovarian Cancer
June 4th 2017Patients with recurrent, platinum-sensitive ovarian cancer and germline <em>BRCA</em> mutations had significant improvement in progression-free survival (PFS) with no decrement in health-related quality of life (hr-QoL) during maintenance therapy with olaparib (Lynparza), according to a review of patient-reported outcomes in a randomized trial.
Read More
ProfiLER Study Demonstrates Importance of Genomic Testing for Precision Medicine
June 4th 2017Comprehensive genomic testing is not yet widespread, but a French study presented at the 2017 ASCO Annual Meeting suggested that DNA profiling can be of important value in advancing personalized medicine. Patients who received molecularly targeted agents based on genomic profiles had longer 3-year and 5-year overall survival than those who did not.
Read More
Pooled Data of Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer Show Promise
June 4th 2017Mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, showed promising activity in patients with platinum-resistant ovarian cancer who had received 1 to 3 prior lines of therapy.
Read More
The PARP inhibitor olaparib (Lynparza) provides clinically significant, long-term treatment benefits in patients with platinum-sensitive relapsed serous ovarian cancer, according to the protocol-specified final overall survival (OS) analysis of the phase II Study 19 trial presented during the 2017 ASCO Annual Meeting.
Read More
Results for Maintenance Olaparib in BRCA-Mutated Platinum-Sensitive Ovarian Cancer
June 4th 2017Michael Birrer, MD, PhD, Director, University of Alabama Comprehensive Cancer Center, discusses adverse event results of the phase III SOLO2 trial, which explored maintenance olaparib (Lynparza) tablets in patients with <em>BRCA</em>-mutated platinum-sensitive relapsed serous ovarian cancer.
Watch
A new, high-intensity genomic sequencing approach for circulating tumor DNA uncovered at least 1 genetic change in both the tumor DNA and the blood of 89% of patients, demonstrating a high rate of concordance between 2 approaches for detecting molecular aberrations, according to a study presented at the 2017 ASCO Annual Meeting.
Read More
Abemaciclib Added to Fulvestrant Improves Response in HR+/HER2- Breast Cancer
June 4th 2017The risk of disease progression or death was reduced by 45% with the addition of abemaciclib to fulvestrant compared with that of fulvestrant alone in patients with previously treated HR-positive/HER2-negative breast cancer, according to findings presented during the 2017 ASCO Annual Meeting.
Read More
Earlier intervention with abiraterone acetate (Zytiga) lowered the risk of death by nearly 40% for men with high-risk advanced or metastatic prostate cancer who were newly diagnosed or had not yet received hormone therapy in findings from 2 clinical trials presented at the 2017 ASCO Annual Meeting.
Read More
Second Surgery Extends Progression-Free Survival in Recurrent Ovarian Cancer With Positive AGO Score
June 4th 2017A second cytoreductive surgery followed by platinum-based chemotherapy extended progression-free survival (PFS) compared with platinum-based chemotherapy alone in patients with relapsed ovarian cancer and a positive Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) score.
Read More
Efficacy Results for LOXO-101 in TRK Fusion Cancers
June 3rd 2017David Hyman, MD, Chief of Early Drug Development, Memorial Sloan Kettering Cancer Center, discusses efficacy results for larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers.
Watch
Updated Results of MONALEESA-2 Trial Maintain Benefit of Ribociclib in HR+/HER2- Breast Cancer
June 3rd 2017Updated results from the phase III MONALEESA-2 trial presented during the 2017 ASCO Annual Meeting confirmed the benefit of frontline ribociclib (Kisqali) in combination with letrozole in patients with postmenopausal hormone receptor (HR)-positive, HER2-negative advanced breast cancer. The combination showed a progression-free survival (PFS) benefit of 9.3 months compared with letrozole plus placebo.
Read More
Survivors of Testicular Cancer At Risk Due to Low Testosterone Levels
June 3rd 2017Chronic health issues, including high blood pressure, diabetes, erectile dysfunction, anxiety, or depression were noted in nearly 40% of testicular cancer survivors with low testosterone levels compared with survivors who had normal levels of testosterone, according to findings from a study that were released at the 2017 ASCO Annual Meeting.
Read More
Efficacy and Biomarker Results for Pembrolizumab in Soft Tissue and Bone Sarcomas
June 3rd 2017Lisa H. Butterfield, PhD, discusses efficacy and biomarker results of the phase II SARC028 study, which explored pembrolizumab (Keytruda) in advanced soft tissue and bone sarcomas, during the 2017 ASCO Annual Meeting.
Watch
Healthy Lifestyle Linked to Improved Overall Survival, Reduced Recurrence in Colon Cancer
May 19th 2017Results from a recent study showed patients with stage III colorectal cancer experienced a 42% lower chance of death and a trend toward reduced cancer recurrence if they maintained a healthy body weight, engaged in regular physical activity, and adopted other healthy lifestyle behaviors.
Read More
Poor Uptake Limits Otherwise Impressive Potential of HPV Vaccine
May 18th 2017Efficacy results for the human papillomavirus (HPV) vaccine continue to be impressive, with newly reported findings showing it reduced the prevalence of high-risk oral HPV infections by 88% in young adults who had at least 1 dose of the vaccine.
Read More
Affordable Care Act Associated With Shift to Earlier-Stage Cancer Diagnosis
May 18th 2017More Stage I cancers were diagnosed after the passage of the Affordable Care Act within 5 screenable disease types (colorectal cancer, female breast cancer, cervical cancer, lung cancer, and prostate cancer) than were diagnosed before ACA implementation.
Read More